טוען...
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...
שמור ב:
| Main Authors: | , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/ https://ncbi.nlm.nih.gov/pubmed/20113498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|